BIONDVAX PHARMACEUTICALS LTD (BVXV)
Institutional ownership reported to the SEC as of Q3 2022, across 16 quarters.
10
Reporting holders
$153.0K
Reported value
0.0%
Held as options
-3
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| ENVESTNET ASSET MANAGEMENT INC | $58.0K | 79,216 | 0.00% | 4q | -51.5%-$61.7K |
| TRUE Private Wealth Advisors | $34.0K | 47,000 | 0.01% | 7q | -15.3%-$6.1K |
| MORGAN STANLEY | $17.0K | 22,590 | 0.00% | 20q | -32.1%-$8.0K |
| RENAISSANCE TECHNOLOGIES LLC | $13.0K | 18,400 | 0.00% | 2q | +0.5% |
| GEODE CAPITAL MANAGEMENT, LLC | $10.0K | 13,768 | 0.00% | 9q | HELD |
| MILLENNIUM MANAGEMENT LLC | $9.0K | 12,275 | 0.00% | new | NEW |
| UBS Group AG | $6.0K | 8,048 | 0.00% | 6q | +71.6%+$2.5K |
| CREDIT AGRICOLE S A | $3.0K | 4,240 | 0.00% | 7q | HELD |
| ROYAL BANK OF CANADA | $2.0K | 2,540 | 0.00% | 16q | HELD |
| Aspire Private Capital, LLC | $1.0K | 1,600 | 0.00% | 3q | HELD |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q3 2022 | 10 | $153.0K | 209,677 | 1 | 2 | 3 | 0.0% |
| Q2 2022 | 13 | $389.0K | 333,825 | 1 | 3 | 4 | 0.0% |
| Q1 2022 | 17 | $544.3K | 329,783 | 8 | 3 | 1 | 0.0% |
| Q4 2021 | 13 | $789.0K | 335,947 | 4 | 3 | 1 | 0.0% |
| Q3 2021 | 15 | $560.0K | 254,692 | 3 | 3 | 3 | 0.0% |
| Q2 2021 | 15 | $891.0K | 311,298 | 4 | 4 | 1 | 0.0% |
| Q1 2021 | 17 | $1.1M | 283,618 | 7 | 1 | 3 | 0.0% |
| Q4 2020 | 11 | $623.0K | 221,696 | 3 | 4 | 2 | 0.0% |
| Q3 2020 | 18 | $21.1M | 539,410 | 10 | 4 | 4 | 0.0% |
| Q2 2020 | 14 | $11.5M | 506,304 | 6 | 4 | 2 | 0.0% |
| Q1 2020 | 8 | $3.1M | 404,629 | 1 | 3 | 1 | 0.0% |
| Q4 2019 | 11 | $4.4M | 476,956 | 2 | 0 | 1 | 0.0% |
| Q3 2019 | 8 | $2.4M | 406,165 | 1 | 0 | 0 | 0.0% |
| Q2 2019 | 7 | $2.3M | 405,665 | 0 | 1 | 0 | 0.0% |
| Q1 2019 | 9 | $2.3M | 417,334 | 0 | 1 | 1 | 0.0% |
| Q4 2018 | 10 | $2.1M | 446,374 | 0 | 0 | 0 | 0.0% |